Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2
Meister et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiaa471 (In Vitro)
Meister et al., Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2, The Journal of Infectious Diseases, doi:10.1093/infdis/jiaa471 (In Vitro)
Jul 2020   Source   PDF  
  All Studies   Meta
In Vitro analysis of 8 oral rinses, showing reduced viral infectivity up to 3 orders of magnitude with povidone-iodine, ethanol + essential oils, and dequalinium chloride + benzalkonium chloride, and log reduction factors ranging from 0.3 to 1.78 for the other 5.
8 In Vitro studies support the efficacy of povidone-iodine [Anderson, Bidra, Frank, Hassandarvish, Meister, Pelletier, Tucker, Xu].
Meister et al., 29 Jul 2020, Germany, peer-reviewed, 12 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Abstract: The Journal of Infectious Diseases BRIEF REPORT Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2 Toni Luise Meister,1 Yannick Brüggemann,1 Daniel Todt,1,2 Carina Conzelmann,3 Janis A. Müller,3 Rüdiger Groß,3 Jan Münch,3 Adalbert Krawczyk,4,5 Jörg Steinmann,6,7 Jochen Steinmann,8 Stephanie Pfaender,1,a and Eike Steinmann1,a The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic creates a significant threat to global health. Recent studies suggested the significance of throat and salivary glands as major sites of virus replication and transmission during early coronavirus disease 2019, thus advocating application of oral antiseptics. However, the antiviral efficacy of oral rinsing solutions against SARS-CoV-2 has not been examined. Here, we evaluated the virucidal activity of different available oral rinses against SARS-CoV-2 under conditions mimicking nasopharyngeal secretions. Several formulations with significant SARS-CoV-2 inactivating properties in vitro support the idea that oral rinsing might reduce the viral load of saliva and could thus lower the transmission of SARS-CoV-2. Keywords. SARS-CoV-2; oral rinses; inactivation; suspension test; transmission. The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has created a significant threat to global health. Since effective treatments and vaccines are currently not available, diligent attention on transmission-based precautions is essential to limit viral spread. According to current evidence, SARS-CoV-2 is mainly transmitted through respiratory droplets exhaled from infected individuals [1]. Importantly, viral loads are high in the nasal cavity, nasopharynx, and oropharynx and viral shedding can be detected before, during, and after the acute clinical phase of illness [2]. Aerosols produced Received 18 June 2020; editorial decision 21 July 2020; accepted 24 July 2020; published online July 29, 2020. a S.P. and E.S. are equally contributing last authors. Correspondence: Eike Steinmann, PhD, Department of Molecular and Medical Virology, RuhrUniversity Bochum, Universitaetsstr 150, 44801 Bochum, Germany ( The Journal of Infectious Diseases®  2020;222:1289–92 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: DOI: 10.1093/infdis/jiaa471 METHODS Virus Strains and Propagation To isolate SARS-CoV-2 at the University Ulm Medical Center (Ulm, Germany), 50 000 Vero E6 cells were seeded in 24-well plates in 500 µL medium incubated overnight at 37°C. The next day, medium was replaced by 400 µL of 2.5 µg/mL amphotericin B–containing medium. Then, 100 µL of throat swabs that tested positive for SARS-CoV-2 by reverse-transcription quantitative polymerase chain reaction was titrated 5-fold on the cells and incubated for 3–5 days. Upon visible cytopathic effect, supernatant was taken and virus expanded by inoculation of Vero E6 cells in 75 cm2 flasks and propagated as described above. Thereby, the viral isolates BetaCoV/Germany/Ulm/01/2020 (strain 2) and BetaCoV/Germany/Ulm/02/2020 (strain 3) were obtained. In Essen, Germany, SARS-CoV-2 was isolated from a nasopharyngeal swab of a patient suffering from coronavirus disease 2019 (COVID-19) and named UKEssen strain (strain 1). The swab was taken using a Virocult vial (Sigma, Germany). The..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop